Oxford Capital has led a $10m round for Oxitec, a UK-based biotechnology company that focuses on controlling insect populations that carry disease or damage crops.
De Scorbiac was responsible for the Accenture Venture fund's activities in Europe
GP sells the Dutch employment agency to its CEO, ending its three-years ownership
Financing for the acquisition was provided by Santander Corporate and Commercial Banking
Sussex Place Ventures, Contour Ventures, Partnership Fund and Outrun Ventures also take part